Please provide your email address to receive an email when new articles are posted on . Despite a decline in herpes simplex virus type 2 infections over the course of decades, researchers calculated ...

The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...

Background. Herpes simplex virus type 2 (HSV-2) reactivations are associated with increased HIV load, but whether HSV-2 coinfection accelerates HIV disease is unclear. We compared rates of CD4 count ...

Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...

HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...

Eurocine Vaccines AB has reported findings from preclinical studies evaluating its mRNA and protein technology platforms for its therapeutic herpes simplex virus type 2 (HSV-2) vaccine candidates.

WOBURN, Mass. and OXFORD, England, Dec. 14, 2021 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

There's more unwelcome news for sufferers of genital herpes. Less than a year after Genocea's experimental herpes vaccine went down in flames, Vical's VCL-HB01 met the same fate: no efficacy in Phase ...

Molly Rosenberg, Audrey Pettifor, Sheri A. Lippman, Harsha Thirumurthy, Michael Emch, William C. Miller, Amanda Selin, Francesc Xavier Gómez-Olivé, James P. Hughes ...